Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
Earlier Data Showed Better Results For Roche Pairing
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.